Dr Benjamin Moore
Ben Moore joined Excellerate in 2020 with prior drug discovery research experience in large pharma and a PhD in cellular pharmacology. Since joining the company, Ben has played a pivotal role in driving Excellerate’s growth, setting up external collaborations to facilitate expanding capabilities in in vitro compound profiling and leading a number of late-stage mechanism-of-action projects. Ben’s knowledge and skills span a range of platforms and fields, including cell biology, signalling pathways, cellular imaging, IF, HCS, and translation of in silico to in vitro approaches in drug discovery screening. Ben’s current focus is on cell metabolism and phenotypic profiling.